CCIA
KROS icon

Campbell & Co Investment Adviser’s Keros Therapeutics KROS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,630
Closed -$359K – 1248
2025
Q4 		$359K Buy
+17,630
New +$309K 0.02% 934
2023
Q3 		– Sell
-7,745
Closed -$311K – 1083
2023
Q2 		$311K Buy
+7,745
New +$340K 0.06% 648

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Campbell & Co Investment Adviser's KROS Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 17,630 shares — an estimated $359K sold.

Campbell & Co Investment Adviser first reported a position in KROS in Q2 2023 and held it in 2 quarters. The position peaked at $359K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 17,630 Keros Therapeutics shares in Q1 2026, an estimated $359K.
  • Campbell & Co Investment Adviser first reported a position in Keros Therapeutics in Q2 2023 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Keros Therapeutics position peaked at $359K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.